Antibiotic minocycline demonstrates potential as alternative treatment for panic disorder in translational study

New research indicates low-dose minocycline reduces panic attack intensity by targeting brain inflammation, offering a potential alternative to clonazepam.

By: AXL Media

Published: May 2, 2026, 3:41 AM EDT

Source: Information for this report was sourced from the São Paulo Research Foundation (FAPESP)

A New Mechanism for Panic Suppression

A collaborative research effort between major Brazilian universities has identified a promising new application for the antibiotic minocycline in the management of panic disorder. According to findings supported by the São Paulo Research Foundation (FAPESP), the medication exerts an anti-panic effect comparable to clonazepam, a widely prescribed benzodiazepine. Unlike traditional treatments that focus on brain receptors, minocycline appears to work by reducing neuroinflammation. This shift in therapeutic focus could provide relief for the estimated 50% of patients who do not respond to existing psychiatric drugs, marking a significant advancement in the field of translational psychiatry.

Experimental Models and Human Trials

The study utilized a specialized experimental model involving the inhalation of carbon dioxide (CO₂), which triggers the physiological sensation of suffocation characteristic of a panic attack. In experiments conducted at São Paulo State University (UNESP) using mice, subjects treated with minocycline for 14 days showed a marked reduction in panic-driven behaviors, such as jumping. Parallel human trials at the Federal University of Rio de Janeiro (UFRJ) involved 49 diagnosed patients who underwent CO₂ inhalation challenges. The results indicated that those administered low-dose minocycline experienced a significant decrease in the intensity of their induced anxiety symptoms, mirroring the efficacy of the control group treated with clonazepam.

Targeting Neuroinflammation Through Microglia

The underlying biological mechanism of the treatment rests on the drug's interaction with the brain's immune system. Lead researchers Beatriz de Oliveira and Professor Luciane Gargaglioni discovered that minocycline modulates the activity of microglia—cells responsible for the brain's inflammatory response. Patients in the study exhibited lower levels of pro-inflammatory cytokines, such as IL-6 and TNFα, while showing an increase in IL-10, an anti-inflammatory agent. This suggests that panic disorder may be partially driven by nerve cell inflammation rather than purely neurotransmitter imbalances, allowing for a more targeted approach to treatment.